

Michael R Ehrenstein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7982141/publications.pdf>

Version: 2024-02-01

105
papers

13,244
citations

38742

50
h-index

33894

99
g-index

109
all docs

109
docs citations

109
times ranked

13049
citing authors

#	ARTICLE	IF	CITATIONS
1	The synergistic efficacy of hydroxychloroquine with methotrexate is accompanied by increased erythrocyte mean corpuscular volume. <i>Rheumatology</i> , 2022, 61, 787-793.	1.9	3
2	Impact of a mid-urethral synthetic mesh sling on long-term risk of systemic conditions in women with stress urinary incontinence: a national cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 664-670.	2.3	4
3	P282-ANA seroconversion during prior anti-TNF therapy abolishes anti-CCP antibody positivity as a predictor of abatacept retention in rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, .	1.9	0
4	RA-MAP, molecular immunological landscapes in early rheumatoid arthritis and healthy vaccine recipients. <i>Scientific Data</i> , 2022, 9, 196.	5.3	4
5	Increased erythrocyte mean corpuscular volume by methotrexate predicts clinical response in psoriatic arthritis. <i>Rheumatology</i> , 2022, , .	1.9	0
6	An unfavourable outcome following switching intravenous abatacept and tocilizumab to subcutaneous forms during the COVID-19 pandemic. <i>Rheumatology</i> , 2021, 60, 977-979.	1.9	8
7	O07- The increase in erythrocyte mean corpuscular volume by methotrexate is potentiated by hydroxychloroquine and is an early indicator of clinical response in rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, .	1.9	0
8	Early reduction in circulating monocyte count predicts maintenance of remission in patients with rheumatoid arthritis treated with anti-TNF therapy. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1628-1629.	0.9	5
9	Regulatory T cells enhance Th17 migration in psoriatic arthritis which is reversed by anti-TNF. <i>IScience</i> , 2021, 24, 102973.	4.1	2
10	Characterization of disease course and remission in early seropositive rheumatoid arthritis: results from the TACERA longitudinal cohort study. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X21110439.	2.7	6
11	Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus. <i>Annals of Internal Medicine</i> , 2021, 174, 1647-1657.	3.9	64
12	Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan. <i>Trials</i> , 2020, 21, 652.	1.6	4
13	Are treat-to-target and dose tapering strategies for rheumatoid arthritis possible during the COVID-19 pandemic?. <i>Lancet Rheumatology</i> , The, 2020, 2, e454-e456.	3.9	3
14	Methotrexate reduces withdrawal rates of TNF inhibitors due to ineffectiveness in rheumatoid arthritis but only in patients who are seropositive. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1516-1517.	0.9	7
15	Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial. <i>BMJ Open</i> , 2019, 9, e032569.	1.9	35
16	The RA-MAP Consortium: a working model for academia-industry collaboration. <i>Nature Reviews Rheumatology</i> , 2018, 14, 53-60.	8.0	15
17	Regulatory T cells as a biomarker for response to adalimumab in rheumatoid arthritis. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 978-980.e9.	2.9	19
18	Clinical Remission of Sight-Threatening Non-Infectious Uveitis Is Characterized by an Upregulation of Peripheral T-Regulatory Cell Polarized Towards T-bet and TIGIT. <i>Frontiers in Immunology</i> , 2018, 9, 907.	4.8	30

#	ARTICLE	IF	CITATIONS
19	DNA methylation governs the dynamic regulation of inflammation by apoptotic cells during efferocytosis. <i>Scientific Reports</i> , 2017, 7, 42204.	3.3	24
20	Tumor Necrosis Factor (TNF) Bioactivity at the Site of an Acute Cell-Mediated Immune Response Is Preserved in Rheumatoid Arthritis Patients Responding to Anti-TNF Therapy. <i>Frontiers in Immunology</i> , 2017, 8, 932.	4.8	25
21	CD4 T-Cell Dysregulation in Psoriatic Arthritis Reveals a Regulatory Role for IL-22. <i>Frontiers in Immunology</i> , 2017, 8, 1403.	4.8	5
22	Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF-TNF-RII binding in rheumatoid arthritis. <i>Journal of Experimental Medicine</i> , 2016, 213, 1241-1253.	8.5	152
23	The BAFFling effects of rituximab in lupus: danger ahead?. <i>Nature Reviews Rheumatology</i> , 2016, 12, 367-372.	8.0	90
24	The impact of biological therapy on regulatory T cells in rheumatoid arthritis. <i>Rheumatology</i> , 2015, 54, 768-775.	1.9	68
25	Engulfment of Activated Apoptotic Cells Abolishes TGF- β -Mediated Immunoregulation via the Induction of IL-6. <i>Journal of Immunology</i> , 2015, 194, 1621-1627.	0.8	13
26	Cutting Edge: Circulating Plasmablasts Induce the Differentiation of Human T Follicular Helper Cells via IL-6 Production. <i>Journal of Immunology</i> , 2015, 194, 2482-2485.	0.8	114
27	B cell resistance to Fas-mediated apoptosis contributes to their ineffective control by regulatory T cells in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 294-302.	0.9	32
28	Induced CD8 ⁺ FoxP3 ⁺ Treg Cells in Rheumatoid Arthritis Are Modulated by p38 Phosphorylation and Monocytes Expressing Membrane Tumor Necrosis Factor α and CD86. <i>Arthritis and Rheumatology</i> , 2014, 66, 2694-2705.	5.6	18
29	Elevated Serum BAFF Levels Are Associated With Rising Anti-Double-Stranded DNA Antibody Levels and Disease Flare Following B Cell Depletion Therapy in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatism</i> , 2013, 65, 2672-2679.	6.7	128
30	CD19 ⁺ CD24 ^{hi} CD38 ^{hi} B Cells Maintain Regulatory T Cells While Limiting T _H 1 and T _H 17 Differentiation. <i>Science Translational Medicine</i> , 2013, 5, 173ra23.	12.4	564
31	Germinal center B cells govern their own fate via antibody feedback. <i>Journal of Experimental Medicine</i> , 2013, 210, 457-464.	8.5	231
32	Quorum Sensing Contributes to Activated IgM-Secreting B Cell Homeostasis. <i>Journal of Immunology</i> , 2013, 190, 106-114.	0.8	25
33	B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels. <i>Rheumatology</i> , 2012, 51, 1208-1215.	1.9	63
34	Anti-TNF antibody therapy induces IL-17 suppressing regulatory T cells in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2012, 14, .	3.5	0
35	Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy. <i>Arthritis and Rheumatism</i> , 2012, 64, 3129-3138.	6.7	126
36	Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales. <i>Clinical Rheumatology</i> , 2012, 31, 1005-1012.	2.2	13

#	ARTICLE	IF	CITATIONS
37	Regulatory T-cell adoptive immunotherapy: potential for treatment of autoimmunity. Expert Review of Clinical Immunology, 2011, 7, 213-225.	3.0	25
38	Therapeutic potential of Tregs to treat rheumatoid arthritis. Seminars in Immunology, 2011, 23, 195-201.	5.6	15
39	Concurrent oral 4 - Connective tissue disease: OP22. B Cell Numbers and Phenotype at Clinical Relapse Following Rituximab Therapy Differ in SLE Patients According to Anti-Dsdna Antibody Titres. Rheumatology, 2011, 50, iii40-iii42.	1.9	0
40	Regulatory T cells in systemic lupus erythematosus and rheumatoid arthritis. FEBS Letters, 2011, 585, 3603-3610.	2.8	94
41	Human FoxP3+ regulatory T cells in systemic autoimmune diseases. Autoimmunity Reviews, 2011, 10, 744-755.	5.8	298
42	Tuberculosis and anti-TNF treatment: experience of a central London hospital. Clinical Rheumatology, 2011, 30, 399-401.	2.2	24
43	Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells, and suppresses experimental inflammatory arthritis. Arthritis and Rheumatism, 2011, 63, 84-95.	6.7	62
44	A case of pure red cell aplasia and immune thrombocytopenia complicating systemic lupus erythematosus: Responseto rituximab and cyclophosphamide. Lupus, 2011, 20, 1547-1550.	1.6	10
45	Mice Lacking Endogenous IL-10 Produce Producing Regulatory B Cells Develop Exacerbated Disease and Present with an Increased Frequency of Th1/Th17 but a Decrease in Regulatory T Cells. Journal of Immunology, 2011, 186, 5569-5579.	0.8	402
46	Natural IgM Is Required for Suppression of Inflammatory Arthritis by Apoptotic Cells. Journal of Immunology, 2011, 186, 4967-4972.	0.8	98
47	The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. Rheumatology, 2011, 50, 1401-1408.	1.9	81
48	Abnormal CTLA-4 function in T cells from patients with systemic lupus erythematosus. European Journal of Immunology, 2010, 40, 569-578.	2.9	50
49	CD19+CD24hiCD38hi B Cells Exhibit Regulatory Capacity in Healthy Individuals but Are Functionally Impaired in Systemic Lupus Erythematosus Patients. Immunity, 2010, 32, 129-140.	14.3	1,382
50	The importance of natural IgM: scavenger, protector and regulator. Nature Reviews Immunology, 2010, 10, 778-786.	22.7	491
51	Secreted IgM Enhances B Cell Receptor Signaling and Promotes Splenic but Impairs Peritoneal B Cell Survival. Journal of Immunology, 2010, 184, 3386-3393.	0.8	32
52	The yin and yang of regulatory T cells and inflammation in RA. Nature Reviews Rheumatology, 2010, 6, 572-577.	8.0	38
53	Immunoglobulin M Is Required for Protection Against Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice. Circulation, 2009, 120, 417-426.	1.6	221
54	Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 19078-19083.	7.1	183

#	ARTICLE	IF	CITATIONS
55	Selective Targeting of B Cells with Agonistic Anti-CD40 Is an Efficacious Strategy for the Generation of Induced Regulatory T2-Like B Cells and for the Suppression of Lupus in MRL- <i>lpr</i> Mice. <i>Journal of Immunology</i> , 2009, 182, 3492-3502.	0.8	269
56	A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at university college london hospital: The first fifty patients. <i>Arthritis and Rheumatism</i> , 2009, 61, 482-487.	6.7	241
57	Restoring the balance: Harnessing regulatory T cells for therapy in rheumatoid arthritis. <i>European Journal of Immunology</i> , 2008, 38, 934-937.	2.9	23
58	The "short" history of regulatory B cells. <i>Trends in Immunology</i> , 2008, 29, 34-40.	6.8	258
59	Antibodies and other biomarkers " pathological consequences (2). <i>Lupus</i> , 2008, 17, 256-258.	1.6	1
60	Introduction to a systemic lupus erythematosus " biomarkers meeting held at University College London on 23rd and 24th February 2007. <i>Lupus</i> , 2008, 17, 231-231.	1.6	0
61	Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 19396-19401.	7.1	244
62	Immunoregulatory potential of T2-MZP B cells. <i>Future Rheumatology</i> , 2008, 3, 79-84.	0.2	2
63	Increased Positive Selection of B1 Cells and Reduced B Cell Tolerance to Intracellular Antigens in c1q-Deficient Mice. <i>Journal of Immunology</i> , 2007, 178, 2916-2922.	0.8	32
64	If the treatment works, do we need to know why?: the promise of immunotherapy for experimental medicine. <i>Journal of Experimental Medicine</i> , 2007, 204, 2249-2252.	8.5	12
65	Novel Suppressive Function of Transitional 2 B Cells in Experimental Arthritis. <i>Journal of Immunology</i> , 2007, 178, 7868-7878.	0.8	507
66	B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1259-1262.	0.9	145
67	Anti-TNF therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF- β . <i>Journal of Experimental Medicine</i> , 2007, 204, 33-39.	8.5	423
68	B cell depletion in systemic lupus erythematosus. <i>Clinical Medicine</i> , 2007, 7, 57-59.	1.9	1
69	Serum IgM plays an important protective role in murine atherosclerosis. <i>Atherosclerosis</i> , 2007, 193, S3-S4.	0.8	0
70	Cells of the synovium in rheumatoid arthritis. B cells. <i>Arthritis Research and Therapy</i> , 2007, 9, 205.	3.5	35
71	Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 613-620.	6.7	501
72	Atorvastatin Restores Lck Expression and Lipid Raft-Associated Signaling in T Cells from Patients with Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2006, 177, 7416-7422.	0.8	114

#	ARTICLE	IF	CITATIONS
73	Predominant role of IgM-dependent activation of the classical pathway in the clearance of dying cells by murine bone marrow-derived macrophages in vitro. <i>European Journal of Immunology</i> , 2005, 35, 252-260.	2.9	155
74	Natural serum IgM maintains immunological homeostasis and prevents autoimmunity. <i>Seminars in Immunopathology</i> , 2005, 26, 425-432.	4.0	57
75	Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2005, 65, 942-945.	0.9	78
76	Statins: immunomodulators for autoimmune rheumatic disease?. <i>Lupus</i> , 2005, 14, 192-196.	1.6	31
77	Impact of DNA ligase IV on nonhomologous end joining pathways during class switch recombination in human cells. <i>Journal of Experimental Medicine</i> , 2005, 201, 189-194.	8.5	131
78	Statins for Atherosclerosis – As Good as It Gets?. <i>New England Journal of Medicine</i> , 2005, 352, 73-75.	27.0	125
79	Title is missing!. <i>Arthritis Research</i> , 2005, 7, S9.	2.0	1
80	Compromised Function of Regulatory T Cells in Rheumatoid Arthritis and Reversal by Anti-TNF α Therapy. <i>Journal of Experimental Medicine</i> , 2004, 200, 277-285.	8.5	1,112
81	Atorvastatin Inhibits Autoreactive B Cell Activation and Delays Lupus Development in New Zealand Black/White F1 Mice. <i>Journal of Immunology</i> , 2004, 173, 7641-7646.	0.8	113
82	Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2003, 48, 2146-2154.	6.7	424
83	The classical pathway is the dominant complement pathway required for innate immunity to <i>Streptococcus pneumoniae</i> infection in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 16969-16974.	7.1	334
84	Cutting Edge: Selection of B Lymphocyte Subsets Is Regulated by Natural IgM. <i>Journal of Immunology</i> , 2002, 169, 6686-6690.	0.8	65
85	Many paths lead to lupus. <i>Lupus</i> , 2002, 11, 801-806.	1.6	6
86	T cell-B cell interactions. <i>Lupus</i> , 2002, 11, 790-792.	1.6	2
87	An open study of B lymphocyte depletion in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2002, 46, 2673-2677.	6.7	539
88	In vivo and in vitro studies of immunoglobulin gene somatic hypermutation. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2001, 356, 21-28.	4.0	20
89	Switch junction sequences in PMS2-deficient mice reveal a microhomology-mediated mechanism of Ig class switch recombination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 14553-14558.	7.1	136
90	Diversification and Selection Mechanisms for the Production of Protein Repertoires Lessons from the Immune System. <i>Applied Biochemistry and Biotechnology</i> , 2000, 83, 53-62.	2.9	3

#	ARTICLE	IF	CITATIONS
91	Deficiency in Serum Immunoglobulin (Ig)m Predisposes to Development of Igg Autoantibodies. Journal of Experimental Medicine, 2000, 191, 1253-1258.	8.5	226
92	Memory in the Bâ€‘cell compartment: antibody affinity maturation. Philosophical Transactions of the Royal Society B: Biological Sciences, 2000, 355, 357-360.	4.0	59
93	Deficiency in Msh2 affects the efficiency and local sequence specificity of immunoglobulin class-switch recombination: parallels with somatic hypermutation. EMBO Journal, 1999, 18, 3484-3490.	7.8	206
94	Antibody Diversification and Selection in the Mature B-cell Compartment. Cold Spring Harbor Symposia on Quantitative Biology, 1999, 64, 211-216.	1.1	18
95	Monitoring and interpreting the intrinsic features of somatic hypermutation. Immunological Reviews, 1998, 162, 107-116.	6.0	117
96	Genetic, structural and functional properties of an IgG DNA-binding monoclonal antibody from a lupus patient with nephritis. European Journal of Immunology, 1998, 28, 339-350.	2.9	83
97	Hot Spot Focusing of Somatic Hypermutation in MSH2-Deficient Mice Suggests Two Stages of Mutational Targeting. Immunity, 1998, 9, 135-141.	14.3	354
98	Targeted gene disruption reveals a role for natural secretory IgM in the maturation of the primary immune response. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 10089-10093.	7.1	209
99	Functional and modelling studies of the binding of human monoclonal anti-DNA antibodies to DNA. Molecular Immunology, 1996, 33, 471-483.	2.2	62
100	Analysis of immunoglobulin variable region genes of a human IgM antiâ€‘myeloperoxidase antibody derived from a patient with vasculitis. Immunology, 1996, 87, 334-338.	4.4	10
101	Not all stoops are due to osteoporosis.. Annals of the Rheumatic Diseases, 1996, 55, 21-23.	0.9	9
102	Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Kidney International, 1995, 48, 705-711.	5.2	196
103	Comparison of a Monoclonal and Polyclonal Anti-idiotypic Against a Human IgG Anti-DNA Antibody. Journal of Autoimmunity, 1994, 7, 349-367.	6.5	10
104	Utilization of the VH4-21 Gene Segment by Anti-DNA Antibodies from Patients with Systemic Lupus Erythematosus. Journal of Autoimmunity, 1993, 6, 809-825.	6.5	107
105	Autoimmunity associated with infection: leprosy, acute rheumatic fever and Lyme disease. Current Opinion in Immunology, 1991, 3, 930-935.	5.5	22